DVADaVita
Is it safe?
Solid, nothing alarming. Balance sheet to watch.
Mixed, watch the balance sheet Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$36.5M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -51% · now 25% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can DVA take a bad year?
DaVita carries $10.1B of net debt at 3.56× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.56×
Net debt / EBITDA · 3.41× a year ago · the load is going up
- Altman Z-score
- 1.69
Altman Z-score · distress zone, below 1.8
- Interest cover
- 3.58×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $10.8B
- Cash and short-term investments
- $689M
- Net debt
- $10.1B
- EBITDA, trailing twelve months
- $2.84B
- Operating profit, trailing twelve months
- $2.13B
- Total debt / EBITDA
- 3.80×
- Annualised volatilitytwo years of daily moves
- 40%
- Worst drawdown on file
- −51%
- Below its 52-week high
- 25%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Care Facilities
The closest names by size in the same industry